Introduction

Breast cancer is a leading cause of death in women, due primarily to ineffective treatment of metastasis. Metastasis is a multi-step process that involves tumour cell escape from the primary tumour, migration through the body, adhesion and extravasation at the secondary site, initiation of micrometastatic growth and maintenance of growth into clinically detectable macrometastases
. Given the onerous nature of this process, it is not surprising that metastasis is highly inefficient, with the main rate-limiting steps being initiation and maintenance of growth at secondary sites [1] [2] [3] . Taken together with the heterogeneous nature of solid tumours, this metastatic inefficiency suggests that only a small subset of cells can successfully navigate the metastatic cascade and eventually re-initiate tumour growth to form metastases. However, the ability to specifically identify and target this deadly subset of cells has remained elusive. [4, 5] and several types of solid cancer [6] [7] [8] [9] [10] [11] , we and others have speculated that CSCs may represent the subset of tumour cells responsible for metastatic disease [12, 13] . However, while several studies have demonstrated the ability of CSCs to initiate and maintain a primary tumour [6] [7] [8] [9] [10] [11] , the functional contribution of CSCs to metastatic behaviour remains poorly understood.
In light of several pivotal studies demonstrating the existence of 'stem-like' cells or cancer stem cells (CSCs) in leukaemia
In breast cancer, stem-like cells have been prospectively isolated from primary tumours and pleural effusions based on a CD44
ϩ
CD24
Ϫ phenotype [6] . Subsequent [8, 9, 11] and CD44 ϩ CD133 ϩ (prostate cancer) [7] . However, because of the heterogeneous nature of solid cancers, the reliability of using cell surface markers as the sole way to isolate CSCs remains controversial [20] [21] [22] [23] . [24] . Retinoic acid signalling is linked to cellular differentiation during development and plays a role in stem cell self-protection throughout an organism's lifespan [25] . We and others have previously used this isolation strategy alone or in combination with cell surface markers (i.e. CD133) to successfully isolate normal human haematopoietic progenitor cells [26] [27] [28] , and ALDH activity has also been used to identify stem-like subsets in human haematopoietic cancers [29] [30] [31] . A recent study by Ginestier et al. (2007) elegantly demonstrated that expression of ALDH1 in breast tumours was a predictor of poor clinical outcome, and that high ALDH activity selects for both normal and tumorigenic human mammary epithelial cells with stem/progenitor properties [32] . (Fig. S1 ). (Fig. 1A, B and D) . However, MDA-MB-468 cells did consistently express CD133 on their surface, at a level significantly higher than the other cell lines (Fig. 1C) .
Furthermore, human stem cell sources (including tumours) may contain alternate stem/progenitor cell lineages not efficiently isolated using variably expressed cell surface markers. A complementary strategy for identifying stem-like tumour cells involves measurement of aldehyde dehydrogenase (ALDH) activity, an enzyme involved in intracellular retinoic acid production
Therefore, the use of ALDH activity as a purification strategy allows non-toxic and efficient isolation of human stem-like cells based on a developmentally conserved stem/progenitor cell function. Although there is growing evidence supporting the existence of CSCs in solid tumours, what remains less clear is the impact of CSCs on metastatic behaviour. We believe that the dearth of knowledge about CSCs and metastasis is due largely to technical challenges associated with the use of primary human cancer cells in pre-clinical models of metastasis: even in nonobese diabetic/ severe combined immune-deficient (NOD/SCID) mice, it is very difficult to grow primary cells as xenograft tumours
Cell migration and invasion assays
MDA-MB-435, MDA-MB-231 and MCF-7 cell lines did not demonstrate expression of CD133
Human breast cancer cell lines contain sub-populations of cells with enhanced ALDH activity
A complementary strategy for identifying cells with a stem/progenitor phenotype involves measurement of ALDH activity [24] . Human umbilical cord blood was assayed for ALDH activity in order to provide a control for setting up the flow cytometry protocol and for confirming that the assay was working appropriately (Fig. S2) . The MDA-MB-435 cell line did not demonstrate any significant increase in ALDH activity ( Fig. 2A) Fig. 2B and C) . The MCF-7 cell line did not demonstrate any increased ALDH activity (Fig. 2D) . (Fig. 8B) , and to spontaneously metastasize to extrapulmonary organs such as the pancreas and spleen (Fig. 8C ).
Fig. 1 Human breast cancer cell lines contain sub-populations of cells expressing prospective CSC markers. (A-D) Flow cytometry analysis of CD44/CD24 and CD133. Antibodies used included an anti-CD44 antibody (clone IM7) conjugated to fluorescein isothiocyanate (FITC), an anti-CD24 antibody (clone ML5) conjugated to phycoerytherin (PE), an anti-CD133 antibody (clone AC133) conjugated to PE, or appropriate FITC and PE-conjugated IgG isotype controls. (A) MDA-MB-435 cells; (B) MDA-MB-231 cells; (C) MDA-MB-468 cells and (D) MCF-7 cells. Left-hand pan
Discussion
The [8, 41] . During the course of carrying out the present study, Yu et al. (2007) [6] [7] [8] [9] [10] [11] . CD133 is a marker expressed by many types of normal stem cells, including neural and haematopoietic stem cells [9, 11] , and has been shown to play a role in stem cell migration and asymmetric division [43, 44] . CD44 is a cell surface receptor for hyaluronic acid, and is involved in cell adhesion, migration and metastasis of cancer cells [23] . [46] . This, combined with the findings of our study and those of Ginestier et al. (2007) [32] 
